



ASX Release

Yale Joins PTX's Phase 1b/2 AML Clinical Trial

Melbourne, Australia - (15 June, 2016) – Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) is pleased to announce that Yale Cancer Center (**Yale**) in New Haven, Connecticut, USA, will join PTX's Phase 1b/2 clinical trial in acute myeloid leukemia (**AML**), which is shortly expected to recruit its first patient at the Moffitt Cancer Centre (**Moffitt**) in Florida.

The clinical trial will be undertaken with PTX's novel Akt inhibitor PTX-200 plus cytarabine in refractory or relapsed acute leukemias. Approximately 18 patients will be recruited in the Phase 1b component of the trial.

Dr. Thomas Prebet MD, PhD, a highly respected US-based specialist in myeloid malignancies, will lead recruitment at Yale. Dr. Prebet is the Assistant Director of Myeloid Malignancy Research at Yale, where he is working to expand the clinical and translational research program in myeloid malignancies.

Dr. Prebet said, "I am delighted to be part of this exciting trial. AML remains a very challenging disease, especially in the relapse and refractory setting, and there is a need for new, targeted therapies. Earlier Phase 1 hematology clinical trials with PTX's Akt suggest that the drug may have a significant activity in AML. I look forward to commencing recruitment shortly with this promising drug candidate".

Yale Cancer Center is one of the 45 designated National Cancer Institute (**NCI**) comprehensive cancer centres in the US. These centers play a vital role in reducing morbidity and mortality from cancer through scientific research, cancer prevention and innovative cancer treatment.

PTX CEO and Managing Director, Steven Yatomi-Clarke, said "It is a real vote of confidence to have an institution as accomplished and prestigious as Yale as part of our trials. Dr. Prebet's experience as a physician and researcher in AML will be a huge benefit to the trial. PTX is delighted with the calibre of the people joining this trial. Yale's addition to the trial is in keeping with our record of attracting and working with the best people and institutions in their fields".

Yale now joins the Moffitt on the AML trial, which is being led by Professor Jeffrey Lancet, MD. Dr. Lancet was also the Principal Investigator on the recent groundbreaking VYXEOS trial in AML by Celator Pharmaceuticals, Inc (NASDAQ: CPXX), which was recently announced to be acquired for US\$1.5 billion cash by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity



problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440